Another Indian drug manufacturer hit with a Form 483 over recent observations

Tyler Patchen

News Reporter

Several Indian drug manufacturers have been put under a microscope by the FDA, as major generics manufacturers have been hit in recent months by Form …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Another Indian drug manufacturer hit with a Form 483 over recent observations

Tyler Patchen

News Reporter

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Viatris' India-based manufacturing site blocked from shipping 11 generic drugs to US

An­oth­er In­di­an drug man­u­fac­tur­er hit with a Form 483 over re­cent ob­ser­va­tions

Tyler Patchen

News Reporter

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

Another Indian drug manufacturer hit with a Form 483 over recent observations

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Viatris' India-based manufacturing site blocked from shipping 11 generic drugs to US